Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919848 | 1.00 | ATM (0.69) | ATMRAB9AGAAKMT2AMEN1 | |
| SCHEMBL4919831 | 1.00 | ATM (0.69) | ATMRAB9AGAAKMT2AMEN1 | |
| SCHEMBL8901705 | 0.81 | RAB9A (0.67) | ATMRAB9AGAAKMT2AMEN1 | |
| SCHEMBL4919833 | 0.78 | ALDH1A1 (0.64) | ATMRAB9AGAAKMT2AMEN1 | |
| SCHEMBL9024919 | 0.77 | GAA (1.00) | ATMRAB9AGAAKMT2AMEN1 | |
| SCHEMBL5748304 | 0.77 | RAB9A (0.71) | ATMRAB9AGAAKMT2AMEN1 | |
| SCHEMBL5748307 | 0.77 | RAB9A (0.71) | ATMRAB9AGAAKMT2AMEN1 | |
| SCHEMBL5748309 | 0.77 | RAB9A (0.71) | ATMRAB9AGAAKMT2AMEN1 | |
| SCHEMBL4918351 | 0.77 | TDP1 (0.64) | ATMRAB9AGAAKMT2AMEN1 | |
| SCHEMBL4918337 | 0.77 | TDP1 (0.64) | ATMRAB9AGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2008-06-05 | — | — | US | disclosed |
| US-20050256162-A1 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-20030199540-A1 | Fluoroalkyoxybenzylamino derivatives of nitrogen containing heterocycles | LOWE JOHN ADAMS (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030114439-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC. | 2003-06-19 | — | — | US | disclosed |
| US-20020035147-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | PFIZER INC. | 2002-03-21 | — | — | US | disclosed |
| EP-1172106-A2 | Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists | Pfizer Products Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-5773450-A | ANTIINFLAMMATORY AGENTS, CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1998-06-30 | — | — | US | disclosed |
| US-5744480-A | ANTIINFLAMMATORY AGENTS, NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0589924-B1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0589924-A1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES. | PFIZER (US) | 1994-04-06 | — | — | EP | disclosed |
| WO-1993000331-A1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER INC. (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199540-A1 | Fluoroalkyoxybenzylamino derivatives of nitrogen containing heterocycles | FPR1, OPRK1, CNR1 | ATM 2467/4885RAB9A 1932/4885GAA 2512/4885 |
| US-20080132538-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | NMUR2, NMUR1, NMBR | ATM 4126/4885RAB9A 2170/4885GAA 1703/4885 |
| US-20020035147-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | AQP4, NAT1, CNR1 | ATM 3743/4885RAB9A 1642/4885GAA 313/4885 |
| US-20030114439-A1 | Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | AQP4, NAT1, CNR1 | ATM 3743/4885RAB9A 1642/4885GAA 313/4885 |
| US-20050256162-A1 | Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles | FPR3, CX3CR1, FPR1 | ATM 2474/4885RAB9A 1954/4885GAA 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.